Peter Nielsen is the president and CEO of Bio-Path Holdings, a biotechnology company focused on preclinical drug development and planning for Phase 1.
Peter Nielsen is the president and CEO of Bio-Path Holdings, a biotechnology company focused on preclinical drug development and planning for Phase 1 clinical trials. He has stated the company needs $3–5 million in the near term to complete additional preclinical studies and file an Investigational New Drug (IND) application.
Full founder directory · Investor directory · Company funding database · Fundraising library